Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2Completed 2Withdrawn 1

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 3978Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Stomach Neoplasms 2109Rectal Neoplasms 1676Colonic Neoplasms 1629Esophageal Neoplasms 1312Liver Neoplasms 878Neoplasms 633Breast Neoplasms 596Cholangiocarcinoma 525Gastrointestinal Neoplasms 468Neoplasm Metastasis 456Esophageal Squamous Cell Carcinoma 434Lung Neoplasms 422Biliary Tract Neoplasms 277Prostatic Neoplasms 270Ovarian Neoplasms 235Barrett Esophagus 224Adenocarcinoma Of Esophagus 202Gallbladder Neoplasms 191Head and Neck Neoplasms 185Carcinoma, Non-Small-Cell Lung 185Gastrointestinal Stromal Tumors 180Anus Neoplasms 179Recurrence 168Melanoma 162Adenocarcinoma 156Uterine Cervical Neoplasms 153Bile Duct Neoplasms 153

Interventions

dehydroftorafur 2Taxes 2Radiotherapy 2Radiation 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2Platinum 1Nivolumab 1Gemcitabine 1Cisplatin 1Capecitabine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Adenocarcinoma × Gastrointestinal × Clear all
NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT07240766 2026-02-13

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Zhejiang University

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT07080021 2025-07-29

MRD

Ruijin Hospital

Recruiting
119 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT03970252 2024-08-09

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
28 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT02394535 2022-09-02

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
25 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡